PharmTech News

Articles

The companies are entering into a license agreement to provide CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. 

uniQure, CSL Behring Collaborate on Hemophilia B Gene Therapy in Over $1.6-Billion Deal

The companies are expanding their existing collaboration and license agreement to develop mRNA vaccines for infectious diseases.

Sanofi to Expand Collaboration with Translate Bio

The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France. 

Sanofi to Invest $682 Million into New Vaccine Sites

Neurocrine will develop and commercialize seven of Takeda’s pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia.

Takeda and Neurocrine to Collaborate on $2-Billion Deal for Pipeline Program Development

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus. 

FDA Revokes EUA for Hydroxychloroquine

The companies have entered into a collaboration agreement to develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates.

Abbvie and Genmab Announce Antibody Collaboration Worth Over $3.1 Billion

The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.

Fujifilm Corporation to Invest $928 Million into Fujifilm Diosynth Biotechnologies’ Denmark Site

The European Commission is pledging EUR 300 million (US$339 million) to Gavi for vaccines for infectious diseases, in addition to an earlier pledge of more than EUR 1.5 billion (US$1.7 billion) made on May 4, 2020.

EC Pledges Nearly $340 Million Additional Vaccine Funding to Gavi

The collaboration will focus on novel therapeutics targeting RNA-modifying proteins for cancer treatment.

AstraZeneca, Accent Therapeutics in $1.1-Billion Deal for RNA-Modifying Protein Therapeutics

The Gavi advance market commitment for COVID-19 vaccines is a new financing instrument aimed at incentivizing vaccine manufacturers to produce sufficient and affordable quantities of COVID-19 vaccines.

Top News